Home » China Venture Capital »

|| Chinese Decheng Capital and consortium invested $120 million in California genetics firm

decheng usDecheng Capital, a China healthcare investment firm, and a group of other investors announced investment of $120 million in San Francisco genetics firm Invitae.

Invitae is a genetic information company and has raised a total of $207 million from investors to date. It provides a single diagnostic test comprising over 200 genes for $1,500. Decheng Capital, based in Shanghai, provides capital to early and growth stage life science companies and already has stakes in other firms like GeneWeave, GenapSys, SentreHeart, 3SBio, Shenzhen GeneMDx Biotech and SINO Medical Sciences.

To see listing and email addresses of investors from China similar to Decheng Capital, check the Chinese Investors Directory

More details follows

Previous Post: China's Anbang acquired Hilton's NY Waldorf for $1.95 billion
Next Post: Chinese investors led $70 million investment in San Francisco education firm Minerva

| About Us

SinaBeat.com provides insight, analysis and research on private investors from China since 2012.

We cover Private Equity, Venture Capital, Real Estate and Institutional Investors from China, Hong Kong and Macau.

Our Chinese Investors Directory can be used as a reliable source on information about investors from China.

|Subscribe to mailing list

Enter your email address:

Careers  |  Sponsorship |  Sitemap |  Terms  |  Privacy Policy

Copyright 2007 - 2019     SinaBeat.com

Follow us: RSS  |   SinaBeat on Twitter  |   SinaBeat on Facebook  |   SinaBeat on Google+  |   SinaBeat on LinkedIn